BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trontinemab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trontinemab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04639050-670@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Trontinemab: Phase 1/2 readout est. (NCT04639050)
DESCRIPTION:Trontinemab\, phase 1/2\, Alzheimer's Disease.\nStudy: Brainshu
 ttle AD: A Multiple Ascending Dose Study to Investigate the Safety\, Toler
 ability\, Pharmacokinetics\, and Pharmacodynamics of RO7126209 Following I
 ntravenous Infusion in Participants With Prodromal or Mild to Moderate Alz
 heimer's Disease\nEstimated primary completion: 31 July 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/trontinemab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04639050
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170150-670@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07170150)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Clinical
  Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's D
 isease\nEstimated primary completion: 16 February 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07170150
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169578-670@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07169578)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Trontinemab in Participants With Early Symptomatic Alzheimer's Disease\nE
 stimated primary completion: 16 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trontinemab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07169578
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717411-670@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20320730
DTEND;VALUE=DATE:20320731
SUMMARY:Trontinemab: Phase 3 readout est. (NCT07717411)
DESCRIPTION:Trontinemab\, phase 3\, Alzheimer's Disease.\nStudy: A Study of
  Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression
  to Symptomatic Alzheimer's Disease\nEstimated primary completion: 30 July
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trontinemab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077174
 11
URL:https://assetmemo.bio/drug/trontinemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
